Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review
Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current...
Saved in:
Main Authors: | Nikolaos Dervenis, Eleftherios Agorogiannis, Panagiotis Dervenis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001516.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration
by: Hamid Riazi-Esfahani, et al.
Published: (2025-02-01) -
Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration
by: Gábor G. Deák, et al.
Published: (2025-02-01) -
Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
by: Francisco Rodríguez, et al.
Published: (2024-05-01) -
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study
by: Øystein Kalsnes Jørstad, et al.
Published: (2024-12-01) -
Saffron therapy for the ongoing treatment of age-related macular degeneration
by: Peter J McCluskey, et al.
Published: (2024-07-01)